$POM

POMDOCTOR LIMITED (NASDAQ: POM) said it is upgrading its online chronic-disease platform to position itself as infrastructure for predictive healthcare data and services. The plan integrates wearables, AI analytics, physician services, real-world healthcare data, and payment networks, aiming to shift care from reactive treatment to proactive monitoring and long-term management.

POMDOCTOR Ltd (POM) has filed an initial insider ownership report (Form 3) for Luo Guoji, identifying him as both a director and Vice President of the company. The filing, dated March 31, 2026, indicates his new insider status but reports no transactions in POMDOCTOR Ltd securities. This establishes Luo Guoji's reporting requirements for future beneficial ownership changes.

Holzer & Holzer, LLC is reminding investors of the April 6, 2026, lead plaintiff deadlines for several shareholder class action lawsuits. These lawsuits are filed against BlackRock TCP Capital Corp. (TCPC), Mereo BioPharma Group plc (MREO), POMDOCTOR LIMITED (POM), and Ultragenyx Pharmaceutical Inc. (RARE). The firm encourages investors who suffered significant losses during the specified periods to contact them to discuss their legal rights.

The Rosen Law Firm is encouraging investors of PomDoctor Ltd. (NASDAQ: POM) to secure legal counsel by the April 7, 2026, lead plaintiff deadline for a securities class action lawsuit. The lawsuit alleges that PomDoctor was involved in a fraudulent stock promotion scheme, with insiders using offshore accounts to dump shares during a price inflation campaign. The firm, known for its success in securities class actions, is offering representation on a contingency fee basis.